Aclarion
-
Spine
Aclarion Announces Publication of Compelling Peer-Reviewed Data in International Journal of Spine Surgery Supporting Nociscan as a Gold Standard for Noninvasive Identification of Painful Lumbar Discs
Confirms predictive value of Nociscan for identifying painful discs. Nociscan demonstrated a sensitivity of 100% and a specificity of 80%…
Read More » -
Financial
Aclarion Announces Pricing of $3.0 Million Public Offering
BROOMFIELD, CO, Feb. 26, 2024 (GLOBE NEWSWIRE) — via NewMediaWire — Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology…
Read More » -
Financial
Aclarion Announces Successful Financings; Plans to Launch CLARITY Trial and Provides Update on Next Steps of Alphatec Strategic Partnership
Company is initiating its pivotal multicenter, prospective, randomized CLARITY trial to build on clinical evidence demonstrating superior surgical outcomes when…
Read More » -
Neuro
Aclarion Expands Nociscan Access Into Phoenix With Key Opinion Leader Surgeon Advisor Juan Uribe, MD
Dr. Uribe is Chief of the Division of Spinal Disorders, Volker K. H. Sonntag Chair of Spine Research, and Vice…
Read More » -
Spine
Aclarion Announces Updated Product Release That Expands MRI Scanner Access for Nociscan Solution
Nociscan is the first augmented intelligence platform to measure pain biomarkers in the lumbar spine This new product release expands…
Read More » -
Spine
Aclarion and ATEC Execute Strategic Partnership Agreement to Advance Commercialization of Nociscan
Partnership aims to include Aclarion’s surgical decision support technology within ATEC’s AlphaInformatiX platform to better inform spine surgery Aclarion’s Nociscan…
Read More » -
Financial
Aclarion Announces Reverse Stock Split
BROOMFIELD, CO, Jan. 02, 2024 (GLOBE NEWSWIRE) — via NewMediaWire — Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare…
Read More » -
Spine
Aclarion Announces Key Commercial Milestone With Completion of 1,000 Nociscan Exams
Pace of Nociscan orders accelerated 2.5x for the last 250 scans compared to the first 250 scans Further acceleration of…
Read More » -
Spine
Aclarion Announces Achievement of Goal to Enroll 10 Leading Spine Surgery Key Opinion Leaders (KOLs) to Support Nociscan Adoption
Recruitment of a panel of leading KOL surgeons who believe Nociscan can improve the diagnosis and treatment of discogenic low…
Read More » -
Neuro
Aclarion Expands Immediate Nociscan Access Into New York City With Tenth Key Opinion Leader Surgeon Advisor Addition Roger Hartl, MD
Dr. Hartl is the Hansen-MacDonald Professor of Neurological Surgery and Director of Spinal Surgery at the Weill Cornell Brain and…
Read More » -
Spine
Aclarion Announces Signing of Commercial Agreement With Porter Hospital, an AdventHealth facility, to Bring Nociscan Technology to Denver
Porter Hospital Becomes First Facility in Denver to Give Chronic Low Back Pain Patients Access to Revolutionary Nociscan Technology That…
Read More » -
Spine
Aclarion Announces Signing Strategic Partnership Letter of Intent With ATEC to Advance Commercialization of Nociscan
Partnership aims to include Aclarion’s Nociscan surgical decisioning technology within ATEC’s AlphaInformatiX platform to better inform spine surgery ATEC is…
Read More » -
Spine
Aclarion Provides Updated Investor Presentation and Corporate Update
Aclarion is steadily executing on a proven path toward standard of care. Ten prominent Key Opinion Leader (KOL) surgeons have…
Read More » -
Financial
Aclarion, Inc. Announces Filing of Delayed 10-Q Quarterly Report
BROOMFIELD, CO, Aug. 25, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare…
Read More » -
Financial
Aclarion Announces Statistically Significant Nociscan® Cost-Effectiveness Abstract Presented at ISASS Annual Meeting
Nociscan cost-effectiveness abstract highlights dominance over provocative discography and can save the US healthcare system $283M to $441M annually. The…
Read More »